Indira Arnautovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Indira Arnautovic has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Richard K. Burt
Northwestern University (retired), Scripps hematology, La Jolla, USA
5 shared publications Xiaoqiang Han
Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, United States
5 shared publications- Kathleen Quigley
Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
4 shared publications Basil Sharrack
Academic Department of Neuroscience and Sheffield NIHR Translational Neuroscience BRC, Sheffield Teaching Hospitals, NHS Foundation Trust University of Sheffield, Sheffield, United Kingdom
3 shared publicationsBorko Jovanovic
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
3 shared publicationsIrene B. Helenowski
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
2 shared publications
Latest Publications
- 1 July 2020
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (1) , 50-59
Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days
We compared three fludarabine-based regimens for systemic sclerosis patients with a high-risk cardiac phenotype that according to EBMT criteria would be a contraindication for a high-dose cyclophosphamide (200 mg/kg) transplant regimen. All three regimens included fludarabine, ATG, and cyclophosphamide (60 mg/kg), while two regimens also included rituximab with or without IVIG. Treatment related mortality (TRM) was 2.4%. The mean number of days of neutropenia (ANC < 500) was 5.2, the mean number of platelet and red blood cell transfusions was 0.3 and 1.85, respectively. Skin score, forced vital capacity (FVC), and total lung capacity (TLC) improved with all three regimens. For patients whose regimen did not include rituximab versus those that included rituximab, 1-year overall relapse rate was higher 36% (5/14) versus 3.6% (1 of 28) (p = 0.01), secondary autoimmune diseases were higher 21% (3/14) versus 0% (0/28) (p = 0.03), and upper respiratory tract infections were higher 28% (4/14) versus 3.6% (1/28) (p = 0.04). In this safety study, a fludarabine-based regimen was relatively safe with a TRM of 2.4% and a neutropenic interval of only 5.2 days in systemic sclerosis patients with a high-risk cardiac phenotype. The addition of rituximab decreased 1-year relapse rate, risk of late secondary autoimmune diseases, and upper-respiratory tract infections.
- 1 July 2020
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (1) , 50-59
Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days
We compared three fludarabine-based regimens for systemic sclerosis patients with a high-risk cardiac phenotype that according to EBMT criteria would be a contraindication for a high-dose cyclophosphamide (200 mg/kg) transplant regimen. All three regimens included fludarabine, ATG, and cyclophosphamide (60 mg/kg), while two regimens also included rituximab with or without IVIG. Treatment related mortality (TRM) was 2.4%. The mean number of days of neutropenia (ANC < 500) was 5.2, the mean number of platelet and red blood cell transfusions was 0.3 and 1.85, respectively. Skin score, forced vital capacity (FVC), and total lung capacity (TLC) improved with all three regimens. For patients whose regimen did not include rituximab versus those that included rituximab, 1-year overall relapse rate was higher 36% (5/14) versus 3.6% (1 of 28) (p = 0.01), secondary autoimmune diseases were higher 21% (3/14) versus 0% (0/28) (p = 0.03), and upper respiratory tract infections were higher 28% (4/14) versus 3.6% (1/28) (p = 0.04). In this safety study, a fludarabine-based regimen was relatively safe with a TRM of 2.4% and a neutropenic interval of only 5.2 days in systemic sclerosis patients with a high-risk cardiac phenotype. The addition of rituximab decreased 1-year relapse rate, risk of late secondary autoimmune diseases, and upper-respiratory tract infections.
- 27 June 2020
- Published by Springer Nature in Journal of Neurology
- Vol. 267 (11) , 3378-3391
Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy
Objective Determine toxicity and efficacy of autologous hematopoietic stem cell transplantation (HSCT) for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are dependent on intravenous immunoglobulins or plasmapheresis. Methods Unselected peripheral blood stem cells were re-infused on day 0 after conditioning with cyclophosphamide 200 mg/kg/intravenously (IV), rATG (thymoglobulin) 5.5 mg/kg/IV, and rituximab 1000 mg/IV. Results Sixty-six patients underwent HSCT for CIDP. Data on sixty patients with a mean follow-up of 4.5 years (range 2–5 years) were available for analysis. There were no treatment-related deaths, and overall survival was 97%. Post-transplant immune medication-free remission was 80%, 78%, 76% 78%, and 83% at 1, 2, 3, 4, and 5 years. Ambulation without assistance improved from 33% pre-HSCT to 82% 82%, 81%, 86%, and 83% at 1, 2, 3, 4, and 5 years, respectively. Mean right/left hand grip strength (kg) improved significantly (all p values < 0.01) from 18.1/16.5 pre-HSCT to 26.3/25.4, 29.2/28.2, 28.8/28.6, 30.3/25.5, and 30.8/29.1 at 1, 2, 3, 4, and 5 years, respectively. Average nerve conduction velocity (NCV) (m/s) improved significantly (all p values ≤ 0.001) from a mean of 27.2 pre-HSCT to 33.5, 33.8, 37.7, 38.2, and 38.3 at 1, 2, 3, 4, and 5 years, respectively. Average compound motor action potential (CMAP) (mv) improved significantly (p values ≤ 0.001) from a mean of 3.6 pre-HSCT to 4.6, 4.6, 5.0, 5.1, and 4.1 at 1, 2, 3, 4, and 5 years, respectively. Conclusion A randomized trial is indicated to verify these results and confirm that HSCT reverses disability and offers long-term immune therapy independence.
- 27 June 2020
- Published by Springer Nature in Journal of Neurology
- Vol. 267 (11) , 3378-3391
Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy
Objective Determine toxicity and efficacy of autologous hematopoietic stem cell transplantation (HSCT) for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are dependent on intravenous immunoglobulins or plasmapheresis. Methods Unselected peripheral blood stem cells were re-infused on day 0 after conditioning with cyclophosphamide 200 mg/kg/intravenously (IV), rATG (thymoglobulin) 5.5 mg/kg/IV, and rituximab 1000 mg/IV. Results Sixty-six patients underwent HSCT for CIDP. Data on sixty patients with a mean follow-up of 4.5 years (range 2–5 years) were available for analysis. There were no treatment-related deaths, and overall survival was 97%. Post-transplant immune medication-free remission was 80%, 78%, 76% 78%, and 83% at 1, 2, 3, 4, and 5 years. Ambulation without assistance improved from 33% pre-HSCT to 82% 82%, 81%, 86%, and 83% at 1, 2, 3, 4, and 5 years, respectively. Mean right/left hand grip strength (kg) improved significantly (all p values < 0.01) from 18.1/16.5 pre-HSCT to 26.3/25.4, 29.2/28.2, 28.8/28.6, 30.3/25.5, and 30.8/29.1 at 1, 2, 3, 4, and 5 years, respectively. Average nerve conduction velocity (NCV) (m/s) improved significantly (all p values ≤ 0.001) from a mean of 27.2 pre-HSCT to 33.5, 33.8, 37.7, 38.2, and 38.3 at 1, 2, 3, 4, and 5 years, respectively. Average compound motor action potential (CMAP) (mv) improved significantly (p values ≤ 0.001) from a mean of 3.6 pre-HSCT to 4.6, 4.6, 5.0, 5.1, and 4.1 at 1, 2, 3, 4, and 5 years, respectively. Conclusion A randomized trial is indicated to verify these results and confirm that HSCT reverses disability and offers long-term immune therapy independence.
- 28 May 2020
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (12) , 2343-2346
A pilot feasibility study of non-myeloablative allogeneic hematopoietic stem cell transplantation for refractory Crohn Disease
- 28 May 2020
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (12) , 2343-2346
A pilot feasibility study of non-myeloablative allogeneic hematopoietic stem cell transplantation for refractory Crohn Disease
- Open Access
- 20 January 2015
- Published by American Medical Association (AMA) in JAMA
- Vol. 313 (3) , 275-284
Association of Nonmyeloablative Hematopoietic Stem Cell Transplantation With Neurological Disability in Patients With Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS) is thought to be an immune-mediated disorder of the central nervous system that in most patients begins as an inflammatory relapsing-remitting disease.1 Despite standard therapies, the majority of patients eventually enter a secondary-progressive phase for which no therapy has demonstrated efficacy. Fifty percent of patients are unable to continue employment by 10 years from diagnosis, require assistance to ambulate by 15 years, or are unable to walk by 25 years.2 Despite an annual cost of approximately US $47 000 per patient3,4 to treat MS, no therapy approved by the US Food and Drug Administration (FDA) has been demonstrated to significantly reverse neurological disability or improve quality of life.5-11
- 20 January 2015
- Published by American Medical Association (AMA) in JAMA
- Vol. 313 (3) , 275-284
Open AccessAssociation of Nonmyeloablative Hematopoietic Stem Cell Transplantation With Neurological Disability in Patients With Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS) is thought to be an immune-mediated disorder of the central nervous system that in most patients begins as an inflammatory relapsing-remitting disease.1 Despite standard therapies, the majority of patients eventually enter a secondary-progressive phase for which no therapy has demonstrated efficacy. Fifty percent of patients are unable to continue employment by 10 years from diagnosis, require assistance to ambulate by 15 years, or are unable to walk by 25 years.2 Despite an annual cost of approximately US $47 000 per patient3,4 to treat MS, no therapy approved by the US Food and Drug Administration (FDA) has been demonstrated to significantly reverse neurological disability or improve quality of life.5-11